Ligand Pharmaceuticals LGND Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$13.35M+68.6% | $44.78M+244% | $117.27M+1,735% | $4.85M+109% | -$42.45M-149% | ||
| $8.22M-6.3% | $8.21M-4.8% | $8.27M-8.1% | $8.52M-3.7% | $8.77M+0.1% | ||
| $10.6M+35.2% | $14.27M+89.7% | $14.75M-2.8% | $10M-9.6% | $7.84M+6.8% | ||
| $13.53M+53.0% | -$10.57M-183% | -$21.28M-1,171% | $325K-98.4% | $8.84M+145% | ||
| $803K+490% | $565K+228% | $447K+234% | $125K+30.2% | $136K+61.9% | ||
| -$6.41M-1,213% | $2.09M-63.2% | $16.31M— | $2.77M-69.4% | $576K+117% | ||
| $4.14M+728% | -$2.77M-8.1% | -$3.59M-85.8% | $875K+135% | $500K+119% | ||
| $2.71M+226% | $7.35M-34.9% | $1.09M-50.9% | -$407K-123% | -$2.15M-55.5% | ||
| -$547K-160% | —— | $205K— | $821K+44.5% | $915K+536% | ||
| $0+100% | —— | —— | -$285K+28.7% | -$293K+45.7% | ||
| -$695K-107% | —— | -$864K-110% | -$2.42M-154% | -$335K+95.6% | ||
| -$732K-3,227% | $174K+314% | $78K-35.5% | -$49K-96.0% | -$22K+76.3% | ||
| $48.69M+291% | $45.92M+61.3% | $13.09M-64.2% | $15.8M+18.7% | -$25.45M-236% | ||
| $228K+6.5% | $9K-98.7% | $15K-97.5% | $214K-47.5% | $214K+104% | ||
| $222.18M+274% | —— | $392.14M+1,143% | $63.34M+159% | $59.37M-23.5% | ||
| $1.3M-96.6% | $120.99M+204% | $185K-99.8% | $0-100% | $38.41M-36.9% | ||
| -$94.35M-2,028% | -$18.1M+53.1% | -$353.45M-660% | -$10.67M+80.5% | $4.89M+230% | ||
| $7.65M+81.3% | $0-100% | -$12.46M-236% | $8.24M-13.7% | $4.22M-72.4% | ||
| $7K0.0% | $7K+16.7% | $6K-40.0% | $7K+75.0% | $7K+40.0% | ||
| $21.73M+144% | $344K-82.2% | $219K+75.2% | $145K— | $8.89M+189% | ||
| $50K-29.6% | $617K+423% | $14.84M+6,966% | $2K-96.5% | $71K+73.2% | ||
| -$14.13M-198% | $8.33M-59.1% | $409.65M+644% | $15M+58.0% | -$4.75M-139% | ||
| -$44K-104% | —— | —— | $2.29M— | $1.06M— | ||
| -$59.83M-146% | $35.55M+309% | $71.71M+57.7% | $19.68M+162% | -$24.32M-190% | ||
| $0+100% | —— | —— | -$2.74M— | -$78K— | ||
| $97K0.0% | $22K+2,100% | $98K-34.7% | $104K+96.2% | $97K+64.4% | ||
| $774K+176% | $2.63M+41.2% | $621K-94.6% | $4.27M-26.0% | $280K— | ||
| $1.5M+79.0% | $2.02M+233% | $1.34M+870% | $766K+78.1% | $839K+434% | ||
| $803K+490% | $565K+228% | $447K+234% | $125K+30.2% | $136K+61.9% | ||
| $21K+106% | -$198K+76.8% | $0— | -$420K+70.4% | -$330K+88.4% | ||
| $479K-16.1% | $480K-15.9% | $479K-16.4% | $412K-18.3% | $571K+19.5% | ||
| —— | $13.27M— | $13.27M— | $13.27M— | $13.27M— | ||
| $3.87M+131% | $22.06M— | —— | —— | -$12.37M-111% | ||
| $13.53M+53.0% | -$10.57M-183% | -$21.28M-1,171% | $325K-98.4% | $8.84M+145% | ||
| -$695K-107% | —— | -$864K-110% | -$2.42M-154% | -$335K+95.6% | ||
| -$624K+66.8% | —— | —— | -$52K+95.8% | -$1.88M-5,794% | ||
| -$4.8M-1,140% | $7.37M+845% | $360K-92.3% | $427K— | $461K— | ||
| -$837K-381% | $1.16M+122% | $111K+101% | -$71K-105% | -$174K-189% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $0-100% | $5.11M— | $1.06M— | $0— | $7.62M— | ||
| $0-100% | $650K— | $8.39M-38.5% | $0-100% | $1.82M-25.5% | ||
| —— | $961.75K+53.9% | $961.75K+53.9% | $961.75K+53.9% | $961.75K+53.9% | ||
| $222.18M+274% | $211.86M+128% | $392.14M+1,143% | $63.34M+159% | $59.37M-23.5% | ||
| $431K— | —— | —— | —— | $0-100% | ||
| $6.98M+122% | $1.5M-41.1% | $3.59M+424% | $2.03M-10.4% | $3.15M+62.2% | ||
| $119.35M+269% | $81.2M+1,409% | $53.29M+1,187% | $50.86M+461% | $32.36M+122% | ||
| $1.3M-96.6% | $120.99M+204% | $185K-99.8% | $0-100% | $38.41M-36.9% | ||
| $7K0.0% | $7K+16.7% | $6K-40.0% | $7K+75.0% | $7K+40.0% | ||
| $50K-29.6% | $617K+423% | $14.84M+6,966% | $2K-96.5% | $71K+73.2% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$59.83M-147% | —— | $71.71M+57.7% | —— | -$24.24M-189% | ||
| $0+100% | —— | —— | -$2.74M— | -$78K— | ||
| $0-100% | —— | —— | $1.49M-14.4% | $828K— | ||
| -$732K-3,227% | $174K+314% | $78K-35.5% | -$49K-96.0% | -$22K+76.3% | ||
| $48.46M+289% | $45.91M+65.4% | $13.08M-63.6% | $15.59M+20.8% | -$25.66M-238% | ||
| $48.46M+289% | $45.91M+65.4% | $13.08M-63.6% | $15.59M+20.8% | -$25.66M-238% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.